
**AUDITORS' REPORT**
**AND**
**THE FINANCIAL STATEMENTS**
**ON**

# Advent Pharma Ltd.

*For the year ended 30th June, 2025*



FAMES & R
CHARTERED ACCOUNTANTS

Hossain Tower (11th Floor), 116 Naya Paltan, Box Culvert Road, Dhaka-1000
Cell: +88 01819 207889, 01819 496565, 01783 294818, 01713 008193, 01675 676963
E-mail: haque.fouzia@gmail.com, hoquezhc@yahoo.com, fmrashid@yahoo.com
shafi.selim1960@gmail.com, dishaarif4@gmail.com

# Independent Auditors' Report
## To the shareholders of Advent Pharma Limited
## Report on the Audit of the Financial Statements

### Opinion

We have audited the financial statements of **Advent Pharma Limited ("the Company"),** which comprise the statement of financial position as at 30 June, 2025 and the statement of profit or loss and other comprehensive income, statement of changes in equity and statement of cash flows for the year then ended, and notes to the financial statements, including summary of significant accounting policies.

In our opinion and to the best of our information and according to the explanations given to us, the accompanying financial statements give true and fair view in all material respects, the financial position of the company as at 30 June, 2025 and of its operational performance & its cash flows for the year then ended in conformity with the International Accounting Standards (IASs) and International Financial Reporting Standards (IFRSs) where applicable, the companies Act 1994, the Securities and Exchange Rules 1987 and other applicable laws and regulations.

### Basis for Opinion

We conducted our audit in accordance with International Standards on Auditing (ISAs). Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountants' Code of Ethics for Professional Accountants (IESBA code) together with the ethical requirements that are relevant to our audit of the financial statements in Bangladesh, and we have fulfilled our other ethical responsibilities in accordance with the IESBA Code and the Institute of Chartered Accountants of Bangladesh (ICAB) Bye Laws. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

### Emphasis of matters

Without modifying our opinion, we would advise the management to ensure compliance with the issues described under Emphasis of matters with immediate action.

1. The company reported Dividend Payable Tk. 3,414,541 which includes TK. 769,271 transferable to the Capital Market Stabilization Fund (CMSF) as directed by the Bangladesh Securities and Exchange Commission's directive no. BSEC/CMRRCD/2021-386/03 dated 14 January 2021 and Bangladesh Securities and Exchange Commission (Capital Market Stabilization Fund) Rules 2021 and Commission's letter no SEC/SRMIC/165-2020/Part-1/166 dated 06 July 2021 and Commission's letter no. SEC/SRMIC/165-2020/part-1/182 dated 9 July 2021.

2. During the audit at the company, we noted that the company made some payments against purchase and expenses in cash mode instead of A/C payee cheque or bank transfer which indicates violation of Income tax ordinance 1984 guideline.

3. As per the section 234 of the Bangladesh Labor Act, 2006, "Establishment of Workers Profit Participation Fund and Welfare fund" - every company is to pay, within 9 (nine) months of the close of every year 5% of profit before tax and transfer to respective "Participatory Fund", "Welfare Fund" and "Workers Welfare Foundation fund" established under section 14 at the ratio of 80:10:10. The Company makes partial payment during the year under audit.

4. The company have not yet introduced employee provident fund and Gratuity/Compensation benefit as per guideline of Bangladesh Labor Laws/Rules 2015, As such no provision have been made for this purpose, which is a non-compliance and misstatement in the financial statement.

**Key Audit Matters**

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the financial statement of the current period. These matters were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

| Risk | Our response to the risk |
|---|---|
| **Revenue recognition** | |
| During the year, the Company recognized sales turnover of BDT 500,490,850 which has decreased by BDT (71,179,751) as compared with previous year.<br><br>Sales revenue recognized by the Company as per IFRS: 15, 'Revenue from Contracts with Customers' & Company Policy. Revenue is recognized based on point of delivery and when relevant performance obligations are satisfied. The company adopted IFRS: 15 'Revenue from Contracts with Customers' as continued from last year.<br><br>We considered sales revenue as an item of significant audit areas during our audit because of its predominance in determining the financial performance of the Company. Sales includes cash collection from customers. | Our audit procedures included the following to test the design and operating effectiveness of key control focusing on:<br>➢ Segregation of duties in invoice creation and modification.<br>➢ Timing of revenue recognition considering step by step procedure.<br>Our substantive procedures in relation to revenue recognition and measurement comprise the following:<br>➢ Obtaining understanding and documenting the process of revenue recognition and measurement followed by the Company.<br>➢ Tracing performance obligations stipulated and contract value in the contract with invoice and delivery challan issued to evaluate point of recognition and measurement.<br>➢ Testing occurrence and accuracy of sales revenue recognized by inspecting source documents such as contract made with the customer, delivery challan and VAT challan.<br>➢ Assessing accuracy and comparing revenue recognized during the year with VAT returns submitted to VAT authority;<br>➢ Finally assessing the appropriateness and presentation of disclosure notes with IFRS 15: Revenue from contracts with customers. |
| See note no. 24, Revenue in the financial statements | |



FAMES & R * DHAKA BANGLADESH * CHARTERED ACCOUNTANTS

| Valuation of closing inventories | |
|---|---|
| Closing inventories aggregating to BDT 66,171,411 was recognized in the statement of financial position as on 30 June 2025. Compared with previous year, this has decreased by BDT (1,067,083).<br><br>Closing inventories were all held at factory premises of the Company. Since determining valuation of these inventories involves management judgments which results in estimation uncertainty, we considered this an area of significant audit attention to be emphasized during the audit. | Our audit responses comprise the following procedures:<br>➢ Evaluating the design and implementation of key inventory control operating across factory premises.<br>➢ Attending and observing the physical inventory at the reporting date.<br>➢ Evaluating compliance with instructions of management count procedures during the count.<br>➢ Inspecting physical stock counting report as on 30 June 2025 and reconciling count results to closing inventories listings and performing test count on selected items to test completeness, accuracy and existence of inventories.<br>➢ Reviewing composition of cost of inventories comprising raw materials, packing materials, work-in-process and finished goods, and comparing net realizable value on selected samples to test their valuation. |
| See note no. 7, Inventories in the financial statements | |
| **Property, plant and equipment** | |
| Property, plant and equipment (PPE) was carried at BDT 1,466,977,873 representing over 80% of total assets of the company as on 30 June 2025. The company reported addition to PPE of BDT 39,808,651 during the year.<br><br>Property, plant and equipment (PPE) are subject to recognition and measurement criteria only after satisfactorily meeting relevant requirement as per IAS 16.<br><br>The company is also required to perform assessment for impairment when there is condition which suggests indication of assets being impaired. | Our audit procedures performed during the audit to address the risks identified consist of the following:<br>➢ Obtaining and documenting detailed understanding regarding procurement process of PPE and identified relevant control points and their implementation.<br>➢ Reviewing recognition, measurement and valuation basis of PPE in compliance with requirement of IAS 16: Property, plant and equipment.<br>➢ Inspecting supporting documents against the acquisition of PPE made during the year to test their accuracy, valuation and ownership in the financial statements. |

| | |
|---|---|
| | ➢ Assessing the appropriateness and presentation of disclosures notes to the financial statements with the requirement of IAS 16 and other relevant IFRSs. |
| See note no. 4, Property, plant and equipment in the financial statements | |
| **Measurement of current year income tax and deferred tax** | |
| During the year, the Company recognized current year income tax of Tk. 5,430,606 and deferred tax Tk. 13,984,183 respectively in the statement of profit or loss and other comprehensive income. Current Tax expenses have increased & Deferred Tax expenses have decreased significantly compared to corresponding expenses recognized in the last year.<br><br>Determination of both current year income tax and deferred tax involves compliance with the Income Tax Act 2023 and latest finance Act along with IAS 12. Income Tax. | Our audit responses adopted during the audit to address the risk identified comprise the following:<br>➢ Obtained and documented management procedures involved in determining both current year income tax and deferred tax.<br>➢ Obtained understanding and reviewed relevant section of the ITO and SRO to test the accuracy of rate applied by the Company.<br>➢ Reviewed rate of depreciation used in determining tax depreciation in compliance with the latest finance act which is used to determine taxable profit and deferred tax.<br>➢ Re-performed detailed calculation of current year income tax and deferred tax as given by the Company.<br>➢ Inspected latest assessment order completed and compared amount of tax paid by the Company with amount recognized in the financial statements. |
| See note no. 23 & 16, income tax & deferred tax expenses in the financial statements | |



FAMES & R DHAKA BANGLADESH CHARTERED ACCOUNTANTS

| Bank Loan | |
|---|---|
| As refereed note no 13 & 14 in the financial statement the company recognized Long Term Borrowings of BDT 7,431,241 and Short-term Borrowings of BDT 58,668,852 respectively at their reporting date.<br><br>Loan liability borrowings from bank were considered s key audit matter because this external form of credit facilities availed by the company require fulfillment of several terms and require fulfillment of several terms and conditions as mentioned in loan sanction letter issued by lending bank. | ➢ Our substantive audit procedure adopted during the audit includes the following test or details<br><br>➢ Inspecting relevant board minutes in support of bank loan reported in the financial statement.<br><br>➢ Agreeing outstanding balances with confirmation letter received from the bank.<br><br>➢ Agreeing finance costs charged by the company with loan statements provided by bank to test accuracy and completeness of expenses in relation to bank loan |

**Other Information**

Management is responsible for the other information. The other information comprises all the information in the annual report other than the financial statements and our auditor's report thereon. The directors are responsible for the other information.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information we are required to report that fact. We have nothing to report in this regard.

**Responsibilities of Management and Those Charged with Governance for the Financial Statements and Internal Controls**

Management is responsible for the preparation and fair presentation of the financial statements in accordance with IFRSs, the Companies Act 1994, the Securities and Exchange Rules 1987 and other applicable laws and regulations and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. The companies Act, 1994 require the management to ensure effective internal audit, internal control and risk management factions of the company

In preparing the financial statements, management is responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so. Those



FAMES & R CHARTERED ACCOUNTANTS DHAKA BANGLADESH

charged with governance are responsible for overseeing the Company's financial reporting process.

**Auditor's Responsibilities for the Audit of the Financial Statements**

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with ISAs, we exercised professional judgment and maintained professional skepticism throughout the audit. We also:

- Identified and assessed the risks of material misstatement of the financial statements, whether due to fraud or error, designed and performed audit procedures responsive to those risks, and obtained audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtained an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances.
- Evaluated the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Concluded on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosers are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the company to cease to continue as a going concern.
- Evaluated the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and event in a manner that achieves fair presentation.
- Obtained sufficient appropriate audit evidence regarding the financial information of the entity to express an opinion on the financial statements. We are solely responsible for our audit opinion.

We communicated with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identified during our audit.

We also provided those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and communicated with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.



FAMES & R DHAKA BANGLADESH CHARTERED ACCOUNTANTS

From the matters communicated with those charged with governance, we determined those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. We described these matters in our auditors' report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determined that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

**Report on Other Legal and Regulatory Requirements**

In accordance with the Companies Act 1994, the Securities and Exchange Rules 1987 and relevant notifications issues by Bangladesh Securities and Exchange Commission, we also report that:

a) we have obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purpose of our audit and made due verification thereof;

b) in our opinion, proper books of accounts, records and other statutory books as required by law, have not been kept by the Company so far as it appeared from our examinations of those books;

c) the statement of financial position and statement of profit or loss and other comprehensive income dealt with by the report are in agreement with the books of account and returns;

d) the expenditures incurred were for the purpose of the Company's business.

Shafi Uddin Ahmed, FCA
Partner
**FAMES & R**
Chartered Accountants
DVC:2510260839AS269279

Date: 26 October, 2025
Place: Dhaka

FAMES & R * DHAKA BANGLADESH * CHARTERED ACCOUNTANTS

# Advent Pharma Ltd.

## Statement of Financial Position

### As at June 30, 2025

| Particulars | Notes | Amount in Tk. | |
|---|---|---|---|
| | | 30-Jun-2025 | 30-Jun-2024 |
| **ASSETS** | | | |
| **NON-CURRENT ASSETS** | | **1,645,929,718** | **1,614,216,768** |
| Property, Plant and Equipment | 4.00 | 1,466,977,873 | 1,489,636,749 |
| Capital Work in Progress (Building Construction) | 5.00 | 178,951,845 | 124,580,019 |
| Right of use Assets | 6.00 | 1,602,786 | 437,129 |
| **CURRENT ASSETS** | | **284,609,783** | **242,079,733** |
| Inventories | 7.00 | 66,171,411 | 67,238,494 |
| Trade and Other Receivable | 8.00 | 188,518,172 | 142,812,450 |
| Advances, Deposits and Pre-payments | 9.00 | 28,150,247 | 28,059,763 |
| Cash and Cash Equivalents | 10.00 | 1,769,953 | 3,969,026 |
| **Total Assets** | | **1,932,142,287** | **1,856,733,630** |
| **SHAREHOLDERS' EQUITY AND LIABILITIES** | | | |
| **SHAREHOLDERS' EQUITY** | | **1,530,367,583** | **1,470,011,919** |
| Share Capital | 11.00 | 931,327,320 | 931,327,320 |
| Retained Earnings | 12.00 | 599,040,263 | 538,684,599 |
| **NON-CURRENT LIABILITIES** | | **212,911,841** | **197,843,382** |
| Long Term Borrowings (Net of Current Portion) | 13.00 | 7,431,241 | 7,431,241 |
| Deferred Tax Liabilities | 16.00 | 204,396,324 | 190,412,141 |
| **Liabilities for lease net current maturity** | 20.00 | 1,084,276 | - |
| **CURRENT LIABILITIES** | | **188,862,863** | **188,878,329** |
| Long Term Borrowings (Current Portion) | 13.00 | 7,912,963 | 7,912,963 |
| Short Term Borrowings | 14.00 | 58,668,852 | 60,000,301 |
| Payable to IPO Applicants | 15.00 | 104,355 | 104,355 |
| Trade and Other Payables | 17.00 | 10,077,197 | 9,637,886 |
| Unclaimed Dividend Account | 18.00 | 476,187 | 749,427 |
| Dividend Payable | 19.00 | 2,938,354 | 10,898,013 |
| Lease liability (Current Portion) | 20.00 | 697,629 | 665,044 |
| Liabilities for expenses | 21.00 | 21,767,892 | 13,561,916 |
| Liability for contribution to W.P.P.F. | 22.00 | 26,100,913 | 30,660,508 |
| Provision for Current Tax | 23.00 | 60,118,522 | 54,687,916 |
| **Total Liabilities** | | **401,774,704** | **386,721,711** |
| **Total Shareholders' Equity and Liabilities** | | **1,932,142,287** | **1,856,733,630** |
| **Net Asset Value (NAV) per Share** | 32.00 | **16.43** | **15.78** |

The annexed notes and Annexure-A are form an integral part of these financial statements.

**Company Secretary** **Chief Financial Officer** **Director** **Managing Director** **Chairman**

Signed as per our annexed report on even date

Shafi Uddin Ahmed, FCA
Partner
**FAMES & R**
Chartered Accountants
DVC:2510260839AS269279

Dated: October 26, 2025
Place: Dhaka

# Advent Pharma Ltd.

## Statement of Profit or Loss and Other Comprehensive Income

**For the Year ended June 30, 2025**

| | Particulars | Notes | Amount in Taka | |
|---|---|---|---|---|
| | | | July 01, 2024 to June 30, 2025 | July 01, 2023 to June 30, 2024 |
| A | Revenues | 24.00 | 500,490,850 | 571,670,601 |
| B | Cost of Sales | 25.00 | (324,524,229) | (343,480,619) |
| C | **Gross Profit** | | **175,966,620** | **228,189,982** |
| | **Operating Expenses** | | **(76,067,524)** | **(76,900,631)** |
| D | Administrative expenses | 26.00 | (23,994,662) | (24,527,964) |
| | Selling & Marketing Expenses | 27.00 | (52,072,862) | (52,372,667) |
| E | **Operating Profit** | | **99,899,096** | **151,289,351** |
| | **Non Operating Expenses** | | **(9,359,023)** | **(12,863,102)** |
| F | Financial Expenses | 28.00 | (9,359,023) | (12,863,102) |
| G | **Other Income** | 29.00 | 62,276 | 153,337 |
| H | **Loss on Sale of Fixed Assets** | 30.00 | - | (29,605,423) |
| I | **Profit Before W.P.P.F** | | **90,602,349** | **108,974,163** |
| J | **Contribution to W.P.P.F** | 22.00 | (4,314,398) | (5,189,246) |
| K | **Profit Before Tax** | | **86,287,951** | **103,784,917** |
| L | **Income Tax Expenses** | | **(19,414,789)** | **(19,792,066)** |
| | Current Tax | 23.00 | (5,430,606) | (4,579,435) |
| | Deferred Tax | 16.00 | (13,984,183) | (15,212,631) |
| M | **Net Profit After Tax** | | **66,873,162** | **83,992,851** |
| N | **Other Comprehensive Income** | | - | - |
| O | **Total Comprehensive Income** | | **66,873,162** | **83,992,851** |
| P | **Earnings per Share (EPS)** | 31.00 | **0.72** | **0.90** |

The annexed notes and Annexure-A are form an integral part of these financial statements.

**Company Secretary** **Chief Financial Officer** **Director** **Managing Director** **Chairman**

Signed as per our annexed report on even date

Shafi Uddin Ahmed, FCA
Partner
**FAMES & R**
Chartered Accountants
DVC:2510260839AS269279

Dated: October 26, 2025
Place: Dhaka

## Advent Pharma Ltd.

### Statement of Changes in Equity

### For the Year ended June 30, 2025

| Particulars | Ordinary Share Capital | Retained Earnings | Total |
|---|---|---|---|
| **Opening Balance as on July 01, 2024** | 931,327,320 | 538,684,599 | 1,470,011,919 |
| Total Comprehensive Income | - | 66,873,162 | 66,873,162 |
| Cash Dividend (2023-2024) | - | (6,517,498) | (6,517,498) |
| **Balance as on June 30, 2025** | **931,327,320** | **599,040,263** | **1,530,367,583** |

## Advent Pharma Ltd.

### Statement of Changes in Equity

### For the Year ended June 30, 2024

| Particulars | Ordinary Share Capital | Retained Earnings | Total |
|---|---|---|---|
| **Opening Balance as on July 01, 2023** | 931,327,320 | 467,726,744 | 1,399,054,064 |
| Total Comprehensive Income | - | 83,992,851 | 83,992,851 |
| Cash Dividend (2022-2023) | - | (13,034,996) | (13,034,996) |
| **Balance as on June 30, 2024** | **931,327,320** | **538,684,599** | **1,470,011,919** |

**Company Secretary** **Chief Financial Officer** **Director** **Managing Director** **Chairman**

Signed as per our annexed report on even date

Dated: October 26, 2025
Place: Dhaka

FAMES & R * DHAKA BANGLADESH * CHARTERED ACCOUNTANTS

# Advent Pharma Ltd.

## Statement of Cash Flows

### For the Year ended June 30, 2025

| Particulars | Notes | Amount in Taka | |
|---|---|---|---|
| | | 30-Jun-2025 | 30-Jun-2024 |
| **A. CASH FLOWS FROM OPERATING ACTIVITIES:** | | | |
| Cash Receipts from Customers & Others | 35.00 | 454,847,403 | 555,505,181 |
| Cash Paid to Suppliers | 36.00 | (248,969,581) | (262,598,532) |
| Cash paid to Employees | 37.00 | (46,798,069) | (49,705,586) |
| Cash paid to Others | 38.00 | (44,092,164) | (65,212,782) |
| Tax Paid During This Year | 39.00 | (243,018) | (2,855,287) |
| **Net cash generated from operating activities** | | **114,744,572** | **175,132,994** |
| **B. CASH FLOWS FROM INVESTING ACTIVITIES:** | | | |
| Paid for Acquisition of Property, Plant & Equipment | 40.00 | (39,808,651) | (53,331,212) |
| Paid for Capital Work -in- Progress (construction) | 41.00 | (54,371,826) | (108,724,739) |
| Proceeds from disposal of Fixed Assets | | - | 2,700,000 |
| **Net cash used for investing activities** | | **(94,180,477)** | **(159,355,951)** |
| **C. CASH FLOWS FROM FINANCING ACTIVITIES:** | | | |
| Net Received/Payment of Short Term Borrowings | | (1,331,449) | 5,008,533 |
| Net Received/Payment of Long Term Borrowings | | - | - |
| Financial Expenses Paid | 43.00 | (5,991,321) | (9,001,205) |
| Interest payment on Lease Liability | | (53,180) | (103,457) |
| Cash Dividend Paid | 42.00 | (14,750,397) | (8,199,468) |
| Principal portion payment of Lease Payment | | (636,820) | (586,543) |
| Refund to IPO Applicants | | 0 | - |
| **Net cash provided by financing activities** | | **(22,763,167)** | **(12,882,140)** |
| **D. Net Increase/(Decrease) in cash & cash equivalents (A+B+C)** | | **(2,199,073)** | **2,894,903** |
| **E. Cash & Cash equivalents at the beginning of the year** | | **3,969,026** | **1,074,123** |
| **F. Cash & Cash equivalents at the end of the year (D+E)** | | **1,769,953** | **3,969,026** |
| **G. Net Operating Cash Flows Per Share** | 33.00 | **1.23** | **1.88** |

**Company Secretary** **Chief Financial Officer** **Director** **Managing Director** **Chairman**

Signed as per our annexed report on even date

Dated: October 26, 2025
Place: Dhaka

# Advent Pharma Ltd.

Rupayan Karim Tower,
Level # 10, 80, Kakrail V.I.P Road,
Ramna, Dhaka-1000.

**Notes, comprising a summary of significant accounting policies and other explanatory information**
**As at and for the year ended 30 June 2025**

## 1.00 Corporate History of the Reporting Entity

Advent Pharma Limited (The Company) was incorporated in Bangladesh as a Private Limited Company under the Companies Act, 1994 vide Registration No. C-65459(2951)/2007 dated 25th January, 2007. Subsequently the company was converted into Public Company Limited by share 07 May 2016.

The registered office of the company and the factory is located at Plot # B50-54, BSCIC Industrial Estate, Dhamrai, Dhaka, Bangladesh.

## 2.00 Corporate Business

The Company is a Pharmaceutical company which is engaged in manufacturing, importing and marketing of animal health care drugs, nutritional supplements and feed additives for livestock like powder, bolus and liquid dosage forms. All products have duly been approved by Drug Administration Authority and Department of Live Stock respectively.

## 3.00 Basis of preparation and significant accounting policies

## 3.01 Basis of Measurement of Elements of Financial Position

The financial statements of the company have been prepared on going concern assumption under historical cost convention, on accrual basis and in accordance with the International Accounting Standards (IASs), International Financial Reporting Standards (IFRSs), the Companies Act 1994, the Securities and Exchange Rules 2020, the requirements of Financial Reporting Act 2015, Value Added Tax and Supplementary Duty Act 2012, Income Tax Ordinance 1984, Income Tax Act 2023 and other laws and regulations applicable for the company.

The following International Accounting Standards were applied for the preparation of the financial statements for the year.

| | |
|---|---|
| IAS 1 | Presentation of Financial Statements |
| IAS 2 | Inventories |
| IAS 7 | Statement of Cash Flows |
| IAS 8 | Accounting Policies, Changes in Accounting Estimates and Errors |
| IAS 10 | Events after the Reporting Period |
| IAS 12 | Income Taxes |
| IAS 16 | Property, Plant and Equipment |
| IAS 19 | Employee Benefits |
| IAS 23 | Borrowing Costs |
| IAS 24 | Related Party Disclosures |
| IAS 32 | Financial Instruments: Presentation |
| IAS 33 | Earnings per Share |
| IAS 36 | Impairment of Assets |
| IAS 37 | Provisions, Contingent Liabilities and Contingent Assets |
| IFRS 7 | Financial Instruments: Disclosures |
| IFRS 8 | Operating Segments |
| IFRS 9 | Financial Instruments |
| IFRS 13 | Fair Value Measurement |
| IFRS 15 | Revenue from Contracts with Customers |
| IFRS 16 | Leases |

FAMES & R DHAKA BANGLADESH CHARTERED ACCOUNTANTS

**3.02 Going Concern Assumption**

Management have assessed the going concern assumptions during the preparation of the financial statements of the company, Management believe that no events or conditions give rise to doubt about the ability of the company to continue in operation in the foreseeable future. This conclusion is drawn based on knowledge of the company, the estimated economic outlook and related identified risks and uncertainties. It has been concluded that it is reasonable to apply the going concern concept as the underlying assumption for the financial statements.

**3.03 Structure, Content and Presentation of Financial Statements**

Being the general purpose financial statements, the presentation of these financial statements is in accordance with the guidelines provided by IAS 1 Presentation of Financial Statements. The financial statements comprises the following;

i) Statement of Financial Position as at June 30, 2025

ii) Statement of Profit or Loss and other comprehensive income for the year ended June 30, 2025

iii) Statement of Changes in Equity for the year ended June 30, 2025

iv) Statement of cash flows for the year ended June 30, 2025

v) Notes, comprising a summary of significant accounting policies and other explanatory information as at and for the year ended June 30, 2025

**3.04 Presentational and Functional Currency**

The figure in the financial statements has been presented in Bangladesh Taka Currency and has been Rounded off to the nearest Taka where necessary.

**3.05 Reporting Period**

The period of the financial statements covers 12(Twelve) months from 01 July 2024 to 30 June 2025.

**3.06 Revenue**

With Compliance of IFRS 15, revenue has been recognized by applying the following five steps:

1. Identify the contract with the customer
2. Identify the performance obligations in the contract
3. Determine the transaction price
4. Allocate the transaction price
5. Recognize revenue when (or as) a performance obligation is satisfied.

We have recognized revenue when all the recognition criteria are met.

**3.07 Lease**

The entity has adopted IFRS 16 from 01 July, 2019 and have been reviewed office rent agreement in light of the new rules in IFRS 16. On adoption of IFRS 16 the entity recognizes a right-of-use asset and a lease liability. The lease liability is measured at the present value of the lease payments that are not paid at date of 01 July, 2019 discounted using the incremental borrowing rate. Subsequently, right-of-use asset is adjusted for depreciation and lease liability is adjusted for interest and lease payments. The lease payment is split into a principal and interest portion which are both presented in the statement of cash flows. Depreciation has been charged on right-of use assets on a straight line basis during the lease period. Incremental borrowing rate is @12%. Lease liability has been calculated following full retrospective method.

### 3.08 Property, Plant and Equipment

**Initial Recognition and measurement**

Property, plant and equipment have been capitalized at cost of acquisition and subsequently stated at cost less accumulated depreciation in compliance with the requirements of IAS 16 Property, Plant and Equipment. The cost of acquisition of an asset comprises its import/ purchase price including non refundable duty taxes and any other directly attributable incidental cost of bringing the assets for its intended use.

**Depreciation on Fixed Assets**

In accordance with the provisions of IAS 16 Property, Plant and Equipment. Depreciation charged on an asset when the assets are available for use. During the year, management of the company has reviewed the depreciation rate of fixed assets as per auditors recommendation. From this Financial year, rate of depreciation on Plant & Machinery has changed to 10% from 5% and on Air Conditioner has changed to 10% from 5% and will be continued. Depreciation is charged on all fixed assets on reducing balance method. The Rate of depreciation for this year as below:

| Particulars | 30-Jun-2025 | 30-Jun-2024 |
|---|---|---|
| Land | - | - |
| Land Development | 2.50% | 2.50% |
| Factory Building | 2.50% | 2.50% |
| Plant & Machinery | 10% | 10% |
| Sub-Station | 10% | 10% |
| Motor Vehicle | 15% | 15% |
| Furniture & Fixture | 10% | 10% |
| Solar Panel | 10% | 10% |
| Generator | 10% | 10% |
| Air Conditioner | 10% | 10% |
| Office Equipment | 10% | 10% |
| HVAC System | 5% | 5% |
| Laboratory Equipment | 5% | 5% |
| Product development Equipment | 5% | 5% |
| ETP | 5% | 5% |
| Books & Journals | 15% | 15% |

**Capital work-in-progress**

Capital work-in-progress represents the cost incurred for acquisition and/or construction of items of property, plant and equipment that were not available for use at the end of 30th June, 2025 and these are stated at cost. The items of capital work in progress are recognized when risks and rewards associated with such assets are transferred to the company.

**Capitalization of borrowing costs**

Borrowing costs that are directly attributable to acquisition, construction or production of a qualifying asset included in the cost of those assets in compliance with IAS 23 Borrowing Costs. However, capitalization of borrowing costs is ceased when acquisition of relevant asset is completed. In this year no borrowing costs have been capitalized.

**3.09 Disposal and Impairment**

An asset is derecognized on disposal or when no future economic benefits are expected from its use and subsequent disposal. Gain or loss arising from the retirement or disposal of an asset is determined as the difference between the net disposal proceeds and the carrying amount of the assets and is recognized as gain or loss from disposal of the asset under other income in the Statement of Profit or Loss and Other Comprehensive Income.

**3.10 Cash and Cash equivalents**

Cash and cash equivalents comprise cash in hand, demand deposits and short term deposit, highly liquid investments that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value.

**3.11 Inventories**

Inventories are carried at the lower of cost or net realizable value as prescribed by IAS 2 Inventories. Cost is determined on weighted average cost basis. The cost of inventories comprises of expenditure incurred in the normal course of business in bringing the inventories to their present location and condition. Net realizable value is based on estimated selling price less any further costs expected to be incurred to make the sale.

**3.12 Events after the Reporting Period**

Events after the Reporting Period that provide additional information about the companies position at the date of statement of Financial position are reflected in the Financial Statements. Events after the reporting period that are non adjusting events are disclosed in the notes when material.

**3.13 Statement of Cash Flows**

The Statement of Cash Flows is prepared in accordance with International Accounting Standards IAS 7 Statement of Cash Flows and cash flows from the operating activities have been presented under direct method considering the provision of paragraph 19 of IAS 7 which provides that "Entities are encouraged to report cash flows from operating activities using the direct method".

As per Bangladesh Securities and Exchange Commission Notification No. BSEC/CMRRCD/2006/158 /208/Admin/81 dated 08 August 2018, Cash Flows from operating activities has been reconciled with net income using the indirect method.

**3.14 Related Party Disclosures**

The company in normal course of business carried out a number of transactions with related parties that fall within the definition of related party as prescribed by IAS 24 Related Party Disclosures. This has been disclosed in a separate note-45 to the financial statements.

**3.15 Earnings Per Share**

The company calculates Earnings per Share (EPS) in accordance with the requirement of IAS 33 Earnings Per Share, which has been shown on the face of the Statement of Profit or Loss and other Comprehensive Income.

**Basic earnings**

This represents earnings for the year ended June 30, 2025 attributable to the ordinary shareholders.

**Basic earnings per share**

This has been calculated dividing the basic earning by the weighted average number of shares outstanding during the year.

**Diluted earnings per share**

No diluted earnings per share is required to be calculated for the year presented as Advent Pharma Ltd. has no dilutive potential ordinary shares.

### 3.16 Impairment of Assets

**I) Financial Assets**

Accounts receivable and others receivables are assessed at each reporting date to determine whether there is any objective evidence of impairment. Financial assets are impaired if objective indicates that a loss event has occurred after the initial recognition of the asset and that the loss event had a negative effect on the estimated future cash flows of that asset that can be estimated reliably. Objective evidence that financial assets are impaired can include default of delinquency by a debtor, indicates that a debtor of issuer will enter bankruptcy etc.

**II) Non-Financial Assets**

An asset is impaired when its carrying amount exceeds its recoverable amount. The company assesses at each reporting date whether there is any indication that an asset may be impaired. If any such indication exits, the company estimates the recoverable amount of the asset. The recoverable amount of an asset is the higher of its fair value less cost to sell and its value in use. Carrying amount of the assets is reduced to its recoverable amount by recognizing an impaired loss is recognized immediately in statement of comprehensive income unless the asset is carried at revalued amount. Any impaired loss of a revalued asset treated as a revaluation decrease.

All fixed and financial assets have been reviewed and it was confirmed that no such assets have been impaired during the year and for this reason no provision has been made for impairment of assets.

### 3.17 Provisions

In accordance with the guidelines as prescribed by IAS 37 "Provisions, Contingent Liabilities and Contingent Assets", provisions are recognized in the following situations:

a) when the company has an obligation (legal or constructive) as a result of past events;

b) when it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation; and

c) when reliable estimates can be made of the amount of the obligation.

### 3.18 Income Tax

**Current Tax**

Provision for taxation has been made as per rates prescribed in Finance Act, 2023 and the Income Tax Ordinance, 1984; and Income Tax Act, 2023 on the profit made by the company.

**Deferred Tax**

The company accounts for deferred tax as per IAS 12 Income Taxes. Deferred Tax is arising due to temporary difference in between carrying amount of book value of assets & liabilities and its tax base. The tax rate prevailing at the balance sheet date is used to determine deferred tax.

### 3.19 Workers Profit Participation Fund (WPPF)

The company has created a fund for workers " Workers profit participation fund (WPPF)" as per Bangladesh Labor Act 2006 (amended 2018) by 5% of profit after charging such expenses.

**3.20 VAT**

Company Produces both Vatable and Non-Vatable Product. The company paid VAT only on vatable items and enjoying exemption for non vatable items as per S.R.O No. 160-AIN/2025/288-VAT, dated: May 27, 2025.

**3.21 Comparative Information**

Comparative information has been disclosed in the respect of previous year for all numeric information in the financial statements and also the narrative and descriptive information where it is relevant for understanding of the current year's financial statement.

**3.22 Financial Instruments**

A financial instrument is any contract that gives rise to a financial asset to one entity and a financial liability or equity instrument to another entity as per IFRS 9 Financial Instruments.

**Financial Assets**

Financial assets of the company include cash and cash equivalents, equity instrument to another entity, Trade receivables and other receivables. The company initially recognize a financial asset in its statement of financial position when, and only when, the company becomes a party to the contractual provision of the instrument. The company derecognize a financial asset when, and only when; the contractual rights to the cash flows from the financial asset expire or transfer the contractual rights to receive the cash flows of the financial asset.

**Financial Liabilities**

The company initially recognize a financial liability in its statement of financial position when, and only when, the company becomes a party to the contractual provision of the instrument. The company derecognize a financial liability from its statement of financial position when, and only when, it is extinguished, that is when the obligation specified in the contract is discharged or cancelled or expires.

**3.23 Employee Benefits**

**The Company's employee benefits include the following:**

**Short Term Employee Benefits**

Short term employee benefits include salaries, bonuses etc. Obligations for such benefits are measured on an discontinued basis are expensed as the related service is provided.

**Worker's profit participation fund (WPPF)**

The company recognized WPPF at the rate of 5% on profit after charging such expenses before tax and payment is made to the workers as per provisions of Bangladesh Labor Act, 2006 (Amended 2018).

**3.24 Operating Segments**

The chief operating decision maker of the company, together with other senior management personnel, reviewed the financial information of the products such as revenue, expenses and allocation of resources. The company performed its operation on aggregate basis and manages the operations as a single operating segment. Hence, it is felt that segment reporting is not required to be disclosed as per IFRS 8 Operating Segments.

**3.25 Other Income**

Other Income arise from Bank Interest Income, Sales of Wastage and Toll charge.

### 3.26 Risk Management

The management of the company is overall responsible for the establishment and oversight of the company's risk management framework. Risk management policies, procedures and systems are reviewed regularly to reflect changes in market conditions and the company's activities. The company has exposure to the following risk for its use of financial instrument.

Credit Risk
Liquidity Risk
Market Risk

**Credit Risk**

Credit risk is the risk of a financial loss to the company if a customer or counterparty to a financial instrument fails to meet its contractual obligations and arises principally from the company's receivables. As at 30 June, 2025 there has no credit risk against receivables.

**Management perception**

To mitigate the credit risk the management of the company follows robust credit control and collection polices. The company has dedicated credit collection team who are responsible for any dues and they have been demonstrating remarkable performance in collecting receivables as per company's credit and collection policy.

**Liquidity Risk**

Liquidity risk is defined as the risk that the company will not be able to settle or meet its financial obligations on time or at a reasonable price.

**Management perception**

The company's approach to managing liquidity is to ensure, as far as possible, that it will always have sufficient liquidity to meet its liabilities when due, under both normal and stressed conditions, without incurring unacceptable losses or risking damage to the company's reputation. Typically, management ensures that it has sufficient cash and cash equivalent to meet expected operational expenses, including the servicing of financial obligation through preparation of the cash forecast, prepared based on time line of payment of the financial obligation and accordingly arrange for sufficient liquidity/ fund to make the expected payment within due date.

**Market Risk**

Market risk is refers to the risk of adverse market conditions affecting the sales and profitability of the company. Mostly, the risk arises from falling demand for the product or service which would harm the performance of the company. On the other hand, strong marketing and brand management would help the company increase their customer base.

**Management perception**

Management is fully aware of the market risk, and act accordingly. Market of animal health products in Bangladesh is growing rapidly. Moreover the company has a strong marketing and brand management to increase the customer base and customer loyalty.

### 3.27 Authorization for Issue

The financial statements were authorized for issue by the board of Directors of the Company on 26 October, 2025.



| Notes | Particulars | Amount in Taka | |
|---|---|---|---|
| | | 30-Jun-2025 | 30-Jun-2024 |
| 4.00 | **Property, Plant and Equipment** | | |
| | **A. Cost** | | |
| | Opening balance | 1,788,844,156 | 1,786,432,275 |
| | Add: Addition during the year | 39,808,651 | 53,331,212 |
| | Less: Disposal during the year | - | (50,919,331) |
| | Closing balance | **1,828,652,807** | **1,788,844,156** |
| | **B. Accumulated Depreciation** | | |
| | Opening balance | 299,207,407 | 252,010,179 |
| | Add: Depreciation charged during the year | 62,467,527 | 65,926,851 |
| | Less: Adjustment during the year | - | (18,729,623) |
| | Closing balance | **361,674,934** | **299,207,407** |
| | **Written down Value (A-B)** | **1,466,977,873** | **1,489,636,749** |
| | Details are shown in Annexure-A. | | |
| 5.00 | **Capital Work In Progress (Building Construction)** | | |
| | Opening balance | 124,580,019 | 15,855,280 |
| | Addition during the year | 54,371,826 | 108,724,739 |
| | **Closing balance** | **178,951,845** | **124,580,019** |
| 6.00 | **Right of use Assets** | | |
| | Opening balance | 437,129 | 1,019,957 |
| | Addition for renewal | 1,748,493 | - |
| | Depreciation expenses | (582,836) | (582,828) |
| | **Closing balance** | **1,602,786** | **437,129** |
| 7.00 | **Inventories** | | |
| | Finished goods (Note-25.00) | 33,877,530 | 35,622,307 |
| | Raw materials (Note-25.01) | 11,079,921 | 12,208,521 |
| | Packing materials (Note-25.02.01) | 5,626,130 | 5,128,914 |
| | Spare parts (Note-25.02.2) | 45,260 | 62,430 |
| | Work In process (Note-25.00) | 15,542,570 | 14,216,322 |
| | **Total** | **66,171,411** | **67,238,494** |
| 8.00 | **Trade & Other Receivables** | | |
| | Trade Receivable | 188,518,172 | 142,812,450 |
| | | **188,518,172** | **142,812,450** |
| | **Ageing of Trade Receivable** | | |
| | More than six months | 18,502,450 | 18,123,455 |
| | Less than six months | 170,015,722 | 124,688,995 |
| | | **188,518,172** | **142,812,450** |

The classification of receivables as required by the Schedule XI of the Companies Act, 1994 are given below:

| | | |
|---|---|---|
| Receivables considered good and in respect of which the company is fully secured. | - | - |
| Receivables considered good for which the company holds no security other than the debtor's personal security. | 188,155,627 | 142,480,754 |
| Receivables considered doubtful or bad. | 362,545 | 331,696 |
| Receivables due by directors or other officers of the company or any of them either severally or jointly with any other person or receivables due by firms or private companies respectively in which any director is a partner or a director or a member. | - | - |
| Receivables due by companies under the same management. | - | - |
| The maximum amount due by directors or other officer of the company at any time during the year. | - | - |
| **Total** | **188,518,172** | **142,812,450** |

| Notes | Particulars | Amount in Taka | |
|---|---|---|---|
| | | 30-Jun-2025 | 30-Jun-2024 |
| 8.01 | **Provision for Bad Debts** | | |
| | Opening balance | 331,696 | 298,899 |
| | Provision for Bad Debts during the year | 30,849 | 32,797 |
| | **Closing balance** | **362,545** | **331,696** |
| 9.00 | **Advances, Deposits & Pre-payments** | | |
| | Advances (Note # 9.01) | 24,420,949 | 24,177,931 |
| | Deposits (Note # 9.02) | 3,671,243 | 3,671,243 |
| | Prepayments (Note # 9.03) | - | 53,724 |
| | VAT Current Account | 58,055 | 156,865 |
| | **Total** | **28,150,247** | **28,059,763** |
| 9.01 | **Advances** | | |
| | Advance against Tax (9.01.01) | 24,420,949 | 24,177,931 |
| | **Total** | **24,420,949** | **24,177,931** |
| 9.01.01 | **Advance against Tax** | | |
| | Opening balance | 24,177,931 | 24,513,639 |
| | Add: Paid during the year (Note-9.01.02) | 243,018 | 2,855,287 |
| | Less: Adjustment During the year (Note-9.01.03) | - | (3,190,995) |
| | **Closing balance** | **24,420,949** | **24,177,931** |
| 9.01.02 | **Tax paid during the year** | | |
| | For the Year 2024-2025 | 43,018 | - |
| | For the Year 2023-2024 | - | 523,157 |
| | For the Year 2021-2022 | - | 832,130 |
| | For the Year 2019-2020 | - | 500,000 |
| | For the Year 2018-2019 | - | 500,000 |
| | For the Year 2017-2018 | 200,000 | - |
| | For the Year 2016-2017 | - | 500,000 |
| | **Total** | **243,018** | **2,855,287** |
| 9.01.03 | **Advance tax adjustment during the year** | | |
| | For the Income year 2021-2022 | - | 3,190,995 |
| | **Total** | **-** | **3,190,995** |
| 9.02 | **Deposits** | | |
| | Security Deposit - Electricity | 550,424 | 550,424 |
| | Security Deposit -Titas Gas Transmission & Distribution Co. Ltd. | 183,000 | 183,000 |
| | Security against-House Rent | 405,000 | 405,000 |
| | Security Deposit -BTCL. | 5,300 | 5,300 |
| | Security against Customs Bill | 2,527,519 | 2,527,519 |
| | **Total** | **3,671,243** | **3,671,243** |
| 9.03 | **Prepayments** | | |
| | **Prepaid Fire Insurance** | | |
| | Opening balance | 53,724 | 53,240 |
| | Add: Advance paid during the year | - | 78,226 |
| | Less: Charged during the year | (53,724) | (77,742) |
| | **Closing balance** | **-** | **53,724** |
| 10.00 | **Cash & Cash Equivalents** | | |
| | Cash in hand (Note-10.01) | 98,738 | 174,572 |
| | Cash at bank (Note-10.02) | 1,671,215 | 3,794,454 |
| | **Total** | **1,769,953** | **3,969,026** |
| 10.01 | **Cash in Hand** | | |
| | Head Office | 69,568 | 152,325 |
| | Depots | 29,170 | 22,247 |
| | **Total** | **98,738** | **174,572** |

Cash in hand has been certified by the management of the company.



FAMES & R DHAKA BANGLADESH

| Notes | Particulars | | Amount in Taka | |
|---|---|---|---|---|
| | | | 30-Jun-2025 | 30-Jun-2024 |
| 10.02 | **Cash at Bank** | | | |
| | **Bank Name** | | | |
| | Islami Bank Bangladesh Ltd. | A/C No. # 283517 | 214,114 | 137,797 |
| | Islami Bank Bangladesh Ltd. | A/C No. # 453011 | 7,729 | 8,591 |
| | Dutch Bangla Bank Ltd. | A/C No. # 129775 | 179,274 | 395,101 |
| | Dutch Bangla Bank Ltd. | A/C No. # 859 | 26,482 | - |
| | Janata Bank Ltd. | A/C No. # 10035785 | 19,576 | 51,293 |
| | IFIC Bank Ltd. | A/C No. # 327-041 | 801,840 | 2,497,400 |
| | IFIC Bank Ltd. | A/C No. # 327-001 | 173,201 | 11,479 |
| | IFIC Bank Ltd. | A/C No. # 327-003 | 31,194 | 14,610 |
| | Shahjalal Islami Bank Ltd. | A/C No. # 000-7339 | 11,452 | 15,487 |
| | Midland Bank Ltd. | A/C No. # 000-6230 | 8,922 | 470,457 |
| | BRAC Bank Ltd. | A/C No. # 150001 | 92,631 | 93,133 |
| | BRAC Bank Ltd. | A/C No. # 150002 | 78,518 | 78,672 |
| | Standard Bank Ltd. | A/C No. # 533012548 | 16,284 | 20,434 |
| | NCC Bank Ltd. | A/C No. # 10015025 | 10,000 | - |
| | **Total** | | **1,671,215** | **3,794,454** |
| 11.00 | **Share Capital** | | | |
| | **Authorized Capital :** | | | |
| | 100,000,000 ordinary shares of Tk. 10.00 each | | **1,000,000,000** | **1,000,000,000** |
| | **Issued, Subscribed & Paid-up Capital :** | | | |
| | 931,32,732 ordinary shares of Tk. 10.00 each | | **931,327,320** | **931,327,320** |

**Share holding position of Shareholders:**

| Category of Shareholders | No. of Share Holding | | Percentage of Shareholding | | Amount in Taka | |
|---|---|---|---|---|---|---|
| | 30-Jun-25 | 30-Jun-24 | 30-Jun-25 | 30-Jun-24 | 30-Jun-25 | 30-Jun-24 |
| Director & Sponsor | 27,957,751 | 27,957,751 | 30.02% | 30.02% | 279,577,510 | 279,577,510 |
| Institutional | 11,572,043 | 12,349,804 | 12.43% | 13.26% | 115,720,430 | 123,498,040 |
| Public | 53,602,938 | 52,825,177 | 57.56% | 56.72% | 536,029,380 | 528,251,770 |
| **Total** | **93,132,732** | **93,132,732** | **100%** | **100%** | **931,327,320** | **931,327,320** |

**The distribution schedule showing the number of shareholders and their share holding in percentage has been disclosed below:**

| Range of Holding | As per BO ID | | Total Share Holdings | % |
|---|---|---|---|---|
| | No. of Holders | Holdings | | |
| Up to 500 Shares | 2,564 | 488,584 | 488,584 | 0.52% |
| 501 to 5,000 Shares | 3,956 | 8,031,111 | 8,031,111 | 8.62% |
| 5,001 to 10,000 Shares | 925 | 7,098,942 | 7,098,942 | 7.62% |
| 10,001 to 20,000 Shares | 550 | 8,109,128 | 8,109,128 | 8.71% |
| 20,001 to 30,000 Shares | 225 | 5,633,642 | 5,633,642 | 6.05% |
| 30,001 to 40,000 Shares | 115 | 4,100,758 | 4,100,758 | 4.40% |
| 40,001 to 50,000 Shares | 79 | 3,649,005 | 3,649,005 | 3.92% |
| 50,001 to 100,000 Shares | 116 | 8,417,809 | 8,417,809 | 9.04% |
| 100,001 to 1,000,000 Shares | 69 | 16,143,333 | 16,143,333 | 17.33% |
| Over 1,000,000 Shares | 9 | 31,460,420 | 31,460,420 | 33.78% |
| **Total** | **8,608** | **93,132,732** | **93,132,732** | **100.00%** |

| | | | |
|---|---|---|---|
| 12.00 | **Retained Earnings** | | |
| | Opening balance | 538,684,599 | 467,726,744 |
| | Add: Profit for the year | 66,873,162 | 83,992,851 |
| | Less: Cash Dividend | (6,517,498) | (13,034,996) |
| | **Closing balance** | **599,040,263** | **538,684,599** |



FAMES & R CHARTERED ACCOUNTANTS DHAKA BANGLADESH

| Notes | Particulars | | Amount in Taka | |
|---|---|---|---|---|
| | | | 30-Jun-2025 | 30-Jun-2024 |
| 13.00 | **Long Term Borrowings Net of Current Portion** | | | |
| | Islami Bank Bangladesh Ltd., A/C # 082015 | | 15,705,691 | 14,177,798 |
| | Islami Bank Bangladesh Ltd., A/C # 100814 | | 2,883,444 | 2,705,367 |
| | **Total** | | **18,589,135** | **16,883,165** |
| | Less: Current Portion of long Term loan | | (7,912,963) | (7,912,963) |
| | Less: Accrued Interest on Long Term Loan | | (3,244,931) | (1,538,961) |
| | **Net Amount** | | **7,431,241** | **7,431,241** |

**Terms and conditions**

This represent the present outstanding balance of the above Long term loans (Project Loan) taken for Construction Works and purchase of Machinery. The above loans are secured by land with building and Existing Machinery. The rate of interest of this loans are varying from 9% -15%.

| | | | | |
|---|---|---|---|---|
| 14.00 | **Short Term Borrowings** | | | |
| | Islami Bank Bangladesh Ltd. | Newmarket Branch | 3,122,589 | 2,956,664 |
| | Islami Bank Bangladesh Ltd. | Newmarket Branch | 5,238,618 | 4,961,096 |
| | Islami Bank Bangladesh Ltd. | Newmarket Branch | 6,729,659 | 6,488,055 |
| | Islami Bank Bangladesh Ltd. | Newmarket Branch | 5,944,076 | 5,730,098 |
| | Islami Bank Bangladesh Ltd. | Newmarket Branch | 11,699,270 | 10,966,110 |
| | Islami Bank Bangladesh Ltd. | Newmarket Branch | 1,012,712 | 947,393 |
| | Islami Bank Bangladesh Ltd. | Newmarket Branch | 915,076 | 862,596 |
| | Islami Bank Bangladesh Ltd. | Newmarket Branch | 821,095 | 773,929 |
| | Islami Bank Bangladesh Ltd. | Newmarket Branch | 586,633 | 552,676 |
| | Islami Bank Bangladesh Ltd. | Newmarket Branch | 961,148 | 906,155 |
| | Islami Bank Bangladesh Ltd. | Newmarket Branch | 585,594 | 552,402 |
| | Islami Bank Bangladesh Ltd. | Newmarket Branch | 410,078 | 386,394 |
| | Islami Bank Bangladesh Ltd. | Newmarket Branch | 515,852 | 484,785 |
| | Islami Bank Bangladesh Ltd. | Newmarket Branch | 1,498,483 | 1,406,750 |
| | Islami Bank Bangladesh Ltd. | Newmarket Branch | 4,033,104 | 3,786,378 |
| | Islami Bank Bangladesh Ltd. | Newmarket Branch | 2,879,218 | 2,703,820 |
| | Islami Bank Bangladesh Ltd. | Newmarket Branch | 2,033,644 | 1,906,019 |
| | Islami Bank Bangladesh Ltd. | Newmarket Branch | 1,004,487 | 941,918 |
| | Islami Bank Bangladesh Ltd. | Newmarket Branch | 1,259,973 | 1,176,262 |
| | Islami Bank Bangladesh Ltd. | Newmarket Branch | 989,124 | 923,578 |
| | Islami Bank Bangladesh Ltd. | Newmarket Branch | 1,261,566 | 1,177,714 |
| | Islami Bank Bangladesh Ltd. | Newmarket Branch | 1,380,639 | 1,288,997 |
| | Islami Bank Bangladesh Ltd. | Newmarket Branch | 12,018,699 | 11,222,023 |
| | Islami Bank Bangladesh Ltd. | Newmarket Branch | 1,466,249 | 1,364,935 |
| | Islami Bank Bangladesh Ltd. | Newmarket Branch | 806,606 | 706,580 |
| | **Total Amount** | | **69,174,192** | **65,173,327** |
| | Less: Accrued Interest on Short Term Loan | | (10,505,340) | (5,173,026) |
| | **Net Amount** | | **58,668,852** | **60,000,301** |

**Terms & Conditions**

This represent the present outstanding balance of the above short term loans (working capital Loan) taken for purchase of Raw materials. The above loans are secured by land with building and Existing Machinery. The rate of interest of this loans are varying from 7% -10%.

| | | | |
|---|---|---|---|
| 15.00 | **Payable to IPO Applicants** | 104,355 | 104,355 |
| | **Total** | **104,355** | **104,355** |

The company issued refund warrant to the IPO applicants but they didn't submit to the bank for receiving the IPO refund money.

| | | | |
|---|---|---|---|
| 16.00 | **Deferred Tax Liabilities** | | |
| | Opening balance | 190,412,141 | 175,199,510 |
| | Add: Provision made during the year (Note-16.01) | 13,984,183 | 15,212,631 |
| | **Closing balance** | **204,396,324** | **190,412,141** |



FAMES & R DHAKA BANGLADESH

| Notes | Particulars | Amount in Taka | |
|---|---|---|---|
| | | 30-Jun-2025 | 30-Jun-2024 |
| 16.01 | **Deferred tax liabilities as at June 30, 2025 is arrived as follows** | | |
| | Written Down Value of P.P.E. as per Accounting Base | 1,466,977,873 | 1,489,636,749 |
| | Written Down Value as per Third Schedule | (558,549,768) | (643,360,567) |
| | **Net Temporary Difference** | **908,428,105** | **846,276,182** |
| | Income Tax Rate | 22.50% | 22.50% |
| | **Deferred Tax Liability** | **204,396,324** | **190,412,141** |
| | Opening Deferred Tax Liability | (190,412,141) | (175,199,510) |
| | **Deferred Tax Expenses** | **13,984,183** | **15,212,631** |
| 17.00 | **Trade and Other payables** | | |
| | **Payable to Suppliers & Others** | | |
| | AMOR VET (LC-196) | 3,776,248 | 3,776,248 |
| | Annex International | 125,437 | 161,252 |
| | Arthosuchak | 6,000 | 6,000 |
| | AR Plastic Industries | 304,498 | - |
| | Banga Building Materials Ltd. | 53,200 | 36,100 |
| | Bengal Remedies Ltd. | 205,103 | 49,757 |
| | Bismillah Plastics | 200,000 | 173,000 |
| | Chemi Trade | 128,375 | 151,025 |
| | Dhaka Foil Corporation | - | 93,469 |
| | Digital Sign Pack | 329,510 | 703,156 |
| | Fortune Advertising | 166,600 | 159,800 |
| | Galaxy Corporation | 138,400 | 180,200 |
| | Greenbee Communications | - | 70,000 |
| | IFAD Autos Limited | 732,320 | 732,320 |
| | Jamuna Corporation | 219,979 | 231,300 |
| | M.A Polymer Industries | - | 184,000 |
| | Moon International | 278,010 | - |
| | Mousumi Traders | 93,376 | 222,500 |
| | M/S Siyam Enterprise | 500,000 | 762,500 |
| | Pakeeza Graphics Design & Printing | 239,985 | 27,675 |
| | Protidiner Sangbad | 40,000 | 8,000 |
| | RDS Industries | 172,745 | 272,500 |
| | Retail Technologies Limited | 240,854 | 211,887 |
| | Ripon Motor Works-Rent A Car | 49,352 | 99,768 |
| | Rupayan Karim Tower Owner's Association | 13,995 | 16,740 |
| | Samin Enterprise | 78,500 | 174,800 |
| | Saumika Printing | 19,920 | - |
| | Six Sigma Group | 244,565 | - |
| | Sky Foils Limited | 258,118 | 111,382 |
| | S.M. Enterprise | 472,821 | 399,195 |
| | Uniscience Pharma | 46,000 | - |
| | S & S Corporation | 287,750 | - |
| | Total Can & Closer Limited | 3,224 | - |
| | UCAS | - | 100,000 |
| | Unique Pharma | 394,411 | 366,912 |
| | Xclusive Can Limited | 257,901 | 156,400 |
| | **Total** | **10,077,197** | **9,637,886** |

This outstanding liabilities are payable to the parties who supplied goods and rendered their services to the company.

| | | | |
|---|---|---|---|
| 18.00 | **Unclaimed Dividend Account** | | |
| | Dividend payable (2018-2019) | 476,187 | 749,427 |
| | **Total** | **476,187** | **749,427** |

| Notes | Particulars | Amount in Taka | |
|---|---|---|---|
| | | 30-Jun-2025 | 30-Jun-2024 |
| 19.00 | **Dividend Payable** | | |
| | Dividend payable (2023-2024) | 2,198,885 | - |
| | Dividend payable (2022-2023) | 244,165 | 7,418,956 |
| | Dividend payable (2021-2022) | 202,220 | 3,185,973 |
| | Dividend payable (2020-2021) | 287,163 | 287,163 |
| | Dividend payable (2020-2021)-Fraction | 3,837 | 3,837 |
| | Dividend payable (2019-2020)-Fraction | 2,084 | 2,084 |
| | **Total** | **2,938,354** | **10,898,013** |
| 20.00 | **Liability for Leases net of current Maturity** | | |
| | Opening balance | 665,044 | 1,256,775 |
| | Add: Addition for renewal | 1,748,493 | - |
| | Add: Interest Expenses | 58,368 | 98,269 |
| | Less: Payment | (690,000) | (690,000) |
| | **Closing balance** | **1,781,905** | **665,044** |
| | Less: Liabilities for lease-current maturity | (697,629) | (665,044) |
| | **Total** | **1,084,276** | **-** |
| 21.00 | **Liabilities for expenses** | | |
| | Electricity bill | 103,486 | 117,171 |
| | Salary and wages | 3,115,069 | 2,866,344 |
| | Director salary | 97,000 | 97,000 |
| | Telephone & mobile bill | 18,395 | 3,630 |
| | Accrued Interest (Note-21.01) | 13,750,271 | 6,711,987 |
| | TDS payable | 20,000 | 20,920 |
| | Other expenses | 893,430 | 926,800 |
| | Provision for bad debts | 362,545 | 331,696 |
| | Legal, license, renewals & professional fee | 3,157,696 | 2,236,368 |
| | Audit fees | 250,000 | 250,000 |
| | **Total** | **21,767,892** | **13,561,916** |
| 21.01 | **Accrued Interest on Loan** | | |
| | Accrued Interest on Long Term Loan (Note-21.01.01) | 3,244,931 | 1,538,961 |
| | Accrued Interest on Short Term Loan (Note-21.01.02) | 10,505,340 | 5,173,026 |
| | **Total Amount** | **13,750,271** | **6,711,987** |
| 21.01.01 | **Accrued Interest on Long Term Loan** | | |
| | Opening balance | 1,538,961 | 449,395 |
| | Add: Interest Charged during the year | 2,305,970 | 1,593,430 |
| | Less: Payment made during the year | (600,000) | (503,864) |
| | **Closing balance** | **3,244,931** | **1,538,961** |
| 21.01.02 | **Accrued Interest on Short Term Loan** | | |
| | Opening balance | 5,173,026 | 1,863,954 |
| | Add: Interest Charged during the year | 6,791,630 | 6,402,671 |
| | Less: Payment made during the year | (1,459,316) | (3,093,599) |
| | **Closing balance** | **10,505,340** | **5,173,026** |
| 22.00 | **Liability for Contribution to W.P.P.F** | | |
| | Provision for W.P.P.F. (Note-22.01) | 18,554,358 | 19,385,003 |
| | Provision for Interest on W.P.P.F.(Note-22.02) | 7,546,555 | 11,275,505 |
| | **Closing balance** | **26,100,913** | **30,660,508** |
| 22.01 | **Provision for WPPF for the year** | | |
| | Opening balance | 19,385,003 | 39,714,036 |
| | Add: Provision for WPPF for the year | 4,314,398 | 5,189,246 |
| | Less: Payment during the year | (5,145,043) | (25,518,279) |
| | **Closing balance** | **18,554,358** | **19,385,003** |
| 22.02 | **Accrued Interest on W.P.P.F Used** | | |
| | Opening balance | 11,275,505 | 11,910,515 |
| | Add: Interest Expenses during the Year | - | 5,164,452 |
| | Less: Interest Expenses Paid | (3,728,950) | (5,799,462) |
| | **Closing balance** | **7,546,555** | **11,275,505** |



FAMES & R DHAKA BANGLADESH CHARTERED ACCOUNTANTS

| Notes | Particulars | Amount in Taka | |
|---|---|---|---|
| | | 30-Jun-2025 | 30-Jun-2024 |
| 23.00 | **Provision for Current Tax** | | |
| | Opening balance | 54,687,916 | 53,299,476 |
| | Add: Provision for tax during the year (Note-23.01) | 5,430,606 | 4,579,435 |
| | Less: Paid during the year/Adjustment (Note-9.01.03) | - | (3,190,995) |
| | **Closing balance** | **60,118,522** | **54,687,916** |
| 23.01 | **Provision for Tax during the year** | | |
| | **(A) Regular** | | |
| | Accounting Profit before Tax | 86,287,951 | 103,784,917 |
| | Add: Other Inadmissible Allowances | - | - |
| | Accounting Depreciation | 62,467,527 | 65,926,851 |
| | Other Income | (220,475) | (5,648,888) |
| | Less: Items for Separate Consideration | - | - |
| | Depreciation as per 3rd Schedule | (124,619,450) | (149,358,723) |
| | **Total Taxable Income** | **23,915,553** | **14,704,157** |
| | **Rate** | **22.50%** | **22.50%** |
| | **Total Tax Expenses/Current Tax** | **5,380,999** | **3,308,435** |
| | **Tax on other income** | **49,607** | **1,271,000** |
| | **Total Tax Payable** | **5,430,606** | **4,579,435** |
| | **(B) Minimum Tax** | | |
| | Revenue from Sales | 500,332,651 | 566,175,050 |
| | Other Income | 220,475 | 5,648,888 |
| | **Total Revenue** | **500,553,125** | **571,823,938** |
| | **Rate of Tax** | **0.60%** | **0.60%** |
| | **Minimum Tax** | **3,003,319** | **3,430,944** |
| | **(C) Advance Tax** | **43,018** | **523,157** |
| | **Provision for the Year (Whichever is Higher)** | **5,430,606** | **4,579,435** |

| Notes | Particulars | Amount in Taka | |
|---|---|---|---|
| | | 30-Jun-2025 | 30-Jun-2024 |

**24.00 Turnover**

**Sales Revenue from Sale of Finished Goods**

| | | |
|---|---|---|
| Gross Sales (Note: 24.01) | 501,077,713 | 567,740,151 |
| Less : VAT on Sales | 745,063 | 1,565,101 |
| **Net Sales** | **500,332,651** | **566,175,050** |
| Toll Manufacturing Income | 158,199 | 5,495,551 |
| **Total Revenue** | **500,490,850** | **571,670,601** |

**24.01 Gross Sales**

Sales Revenue from Sale of Finished Goods

| | Gross Sales | VAT@15% | Net Sales | Net Sales |
|---|---|---|---|---|
| Vatable Sales | 5,712,148 | 745,063 | 4,967,086 | 10,434,008 |
| Non Vatable Sales | 495,365,565 | - | 495,365,565 | 555,741,042 |
| **Total** | **501,077,713** | **745,063** | **500,332,651** | **566,175,050** |

**25.00 Cost of Sales**

| | | |
|---|---|---|
| Raw Materials Consumed (Note-25.01) | 238,049,831 | 252,026,626 |
| Manufacturing Overhead (Note-25.02) | 87,724,797 | 94,863,177 |
| | **325,774,628** | **346,889,803** |
| Add: Opening Work in process | 14,216,322 | 14,523,124 |
| Less: Closing Work in process | (15,542,570) | (14,216,322) |
| **Cost of Goods manufactured** | **324,448,380** | **347,196,605** |
| Add: Opening stock of finished Goods | 35,622,307 | 34,109,497 |
| **Cost of Goods Available for Sale** | **360,070,687** | **381,306,102** |
| Less: Closing stock of finished Goods | (33,877,530) | (35,622,307) |
| Less: Sample Distribution | (1,668,928) | (2,203,176) |
| **Cost of Sales** | **324,524,229** | **343,480,619** |

**25.01 Raw Materials Consumed**

| | | |
|---|---|---|
| Opening Stock of Raw Materials | 12,208,521 | 23,670,264 |
| Add: Raw Materials Purchased (Note-25.01.01) | 236,921,231 | 240,564,883 |
| Raw Materials available for Consumption | **249,129,752** | **264,235,147** |
| Less: Closing Stock of Raw Materials | (11,079,921) | (12,208,521) |
| **Raw Material Consumption** | **238,049,831** | **252,026,626** |

**25.01.01 Raw Materials Purchase**

| | | |
|---|---|---|
| Local Purchase | 236,921,231 | 232,712,747 |
| Foreign Purchase | - | 7,852,136 |
| **Total Purchase** | **236,921,231** | **240,564,883** |

**25.02 Manufacturing Overhead**

| | | |
|---|---|---|
| Wages and salary | 9,592,957 | 11,320,813 |
| Festival bonus | 782,600 | 827,000 |
| Overtime | - | 61,147 |
| Packaging materials consumed (Note # 25.02.01) | 11,151,620 | 12,452,032 |
| Spare parts consumed (Note # 25.02.02) | 977,155 | 892,779 |
| Repair & maintenance | 490,847 | 558,569 |
| Electricity bill | 1,136,908 | 1,302,510 |
| Diesel & fuel | 21,070 | 73,655 |
| Electric & sanitary goods | 85,983 | 86,958 |
| Fire insurance premium | 78,195 | 84,261 |
| Canteen expenses | 1,203,560 | 1,475,170 |
| Conveyance | 40,630 | 42,975 |

Cont....



FAMES & R DHAKA BANGLADESH

| Notes | Particulars | Amount in Taka | |
|---|---|---|---|
| | | 30-Jun-2025 | 30-Jun-2024 |
| | Miscellaneous expenses | 37,907 | 53,198 |
| | Newspaper & magazine | 3,723 | 3,620 |
| | Laboratory expenses | 180,420 | 70,925 |
| | Photocopy, printing & stationery | 35,427 | 84,720 |
| | Cleaning & washing | 69,975 | 71,555 |
| | Internet bill | 40,000 | 31,000 |
| | Mobile & telephone bill | 41,950 | 45,900 |
| | Uniform | 97,970 | 73,960 |
| | Toll charges | 659,556 | 928,511 |
| | Depreciation (Annexure-A) | 60,996,344 | 64,321,919 |
| | **Total** | **87,724,797** | **94,863,177** |
| **25.02.01** | **Packaging Materials Consumed** | | |
| | Opening Stock of Packaging Materials | 5,128,914 | 7,366,928 |
| | Add: Purchase during the year | 11,648,836 | 10,214,018 |
| | Less: Closing Stock of Packaging Materials | (5,626,130) | (5,128,914) |
| | **Packaging Materials Consumed** | **11,151,620** | **12,452,032** |
| **25.02.02** | **Spare Parts Consumed** | | |
| | Opening Stock of Spare Parts | 62,430 | 78,512 |
| | Add: Purchase during the year | 959,985 | 876,697 |
| | Less: Closing Stock of Spare Parts | (45,260) | (62,430) |
| | **Spare Parts Consumed** | **977,155** | **892,779** |
| **26.00** | **Administrative Expenses** | | |
| | Salary & Allowance | 11,117,633 | 11,424,002 |
| | Director Salary (Note # 45.01) | 1,200,000 | 1,200,000 |
| | Conveyance | 88,110 | 54,835 |
| | Subscription, Gift & Donation | 71,235 | 66,253 |
| | Festival Bonus | 566,900 | 583,500 |
| | Board meeting attendance fees (Note # 45.01) | 225,000 | 225,000 |
| | Cleaning & Sanitation | 23,993 | 27,145 |
| | Credit Rating Fee | - | 50,000 |
| | Electricity Bill | 209,856 | 227,391 |
| | Entertainment | 410,695 | 458,640 |
| | Garage Rent | 24,000 | 24,000 |
| | Legal, License & Renewal & Professional fee | 1,417,166 | 1,827,756 |
| | Research & Product Development | 958,800 | 1,020,000 |
| | Miscellaneous Expense | 2,532,399 | 1,964,992 |
| | Newspaper & Magazine | 7,518 | 3,480 |
| | Postage, Stamps & Courier | 32,373 | 34,105 |
| | Printing & Stationery | 836,719 | 366,000 |
| | Office Maintenance | 210,855 | 328,935 |
| | Training Allowance | 25,000 | 46,000 |
| | Repair & Maintenance | 339,494 | 286,605 |
| | Fuel & Gas | 838,038 | 1,274,603 |
| | Telephone & Mobile | 112,069 | 120,462 |
| | Internet bill | 108,000 | 108,000 |
| | Annual General Meeting Expenses | 334,790 | 368,500 |
| | Audit fees (Including VAT) | 250,000 | 250,000 |
| | Depreciation Charge for the Right-of-Use Asset | 582,836 | 582,828 |
| | Depreciation (Annexure-A) | 1,471,183 | 1,604,932 |
| | **Total** | **23,994,662** | **24,527,964** |



FAMES & R DHAKA BANGLADESH

| Notes | Particulars | Amount in Taka | |
|---|---|---|---|
| | | 30-Jun-2025 | 30-Jun-2024 |
| **27.00** | **Selling & Marketing Expenses** | | |
| | Salary & Allowance | 22,103,929 | 22,662,137 |
| | Travelling & Conveyance | 9,293,533 | 8,043,777 |
| | Festival Bonus | 1,457,775 | 867,075 |
| | Advertisement | 118,800 | 145,430 |
| | Marketing Promotion | 7,000,130 | 7,254,046 |
| | Distribution Cost | 10,398,918 | 11,164,229 |
| | Bad Debts Expenses | 30,849 | 32,797 |
| | Sample Distribution | 1,668,928 | 2,203,176 |
| | **Total** | **52,072,862** | **52,372,667** |
| **28.00** | **Financial Expenses** | | |
| | Bank Charges | 203,055 | 316,114 |
| | Interest on Loan | 9,097,600 | 7,996,101 |
| | Interest on W.P.P.F used | - | 4,452,618 |
| | Interest expenses on lease liability | 58,368 | 98,269 |
| | **Total** | **9,359,023** | **12,863,102** |
| **29.00** | **Other Income** | | |
| | Bank Interest | 20,056 | 17,157 |
| | Sales of Wastage | 42,220 | 136,180 |
| | **Total** | **62,276** | **153,337** |
| **30.00** | **Other Loss** | | |
| | Loss on Sale of Fixed Assets | - | 29,489,708 |
| | Loss on Foreign currency exchange rate | - | 115,715 |
| | **Total** | **-** | **29,605,423** |

| | | Yearly Product (Weighted Average) | |
|---|---|---|---|
| **31.00** | **Earnings Per Share** | **30-Jun-2025** | **30-Jun-2024** |
| | Basic Earnings per Share | | |
| | Profit after tax | 66,873,162 | 83,992,851 |
| | Weighted average number of ordinary shares outstanding | 93,132,732 | 93,132,732 |
| | **Basic Earnings per Share** | **0.72** | **0.90** |

As there is no shares under Option, Basic & Diluted earnings per share are same for the year. This has been calculated in compliance with the requirement of IAS 33 Earnings per share. EPS is the basic earnings dividing by the weighted average number of ordinary shares outstanding at the end of the year.

**31.01 Calculation of Weighted Average Number of Shares**

| Particulars | Share Numbers | Outstanding Period | Length in Days | Daily Product | Yearly Product (Weighted Average) | |
|---|---|---|---|---|---|---|
| | | | | | 30-Jun-2025 | 30-Jun-2024 |
| Shares at beginning | 93,132,732 | July-24 to June-25 | 365 | 33,993,447,180 | 93,132,732 | 93,132,732 |
| **Total** | **93,132,732** | | | **33,993,447,180** | **93,132,732** | **93,132,732** |

| Notes | Particulars | Amount in Taka | |
|---|---|---|---|
| | | 30-Jun-2025 | 30-Jun-2024 |
| **32.00** | **Net Asset Value (NAV) per Share** | | |
| | Total Asset | 1,932,142,287 | 1,856,733,630 |
| | Less: Total Outside Liability | 401,774,704 | 386,721,711 |
| | **Net Asset** | **1,530,367,583** | **1,470,011,919** |
| | Number of ordinary shares outstanding | 93,132,732 | 93,132,732 |
| | **Net Assets Value (NAV) per Share** | **16.43** | **15.78** |
| **33.00** | **Net Operating Cash Flows per Share(NOCFPS)** | | |
| | Net Cash Generated From Operating Activities | 114,744,572 | 175,132,994 |
| | Weighted Average Number of Shares Outstanding | 93,132,732 | 93,132,732 |
| | **Net Operating Cash Flows per Share(NOCFPS)** | **1.23** | **1.88** |
| **34.00** | **Reconciliation of Net Profit with Cash flows from Operating Activities** | | |
| | **Profit before Tax** | **86,287,951** | **103,784,917** |
| | Adjustment for: | | |
| | Depreciation on property, plant and equipment | 62,467,527 | 65,926,851 |
| | Adjustment for depreciation of the Right Use of Assets | 582,836 | 582,828 |
| | Interest expenses on Lease | 58,368 | 98,269 |
| | Financial Expenses | 9,300,655 | 12,764,833 |
| | Loss on disposal of Fixed Assets | - | 29,605,423 |
| | Loss on Foreign Currency Exchange | - | (115,715) |
| | | **158,697,337** | **212,647,405** |
| | (Increase)/Decrease in Accounts Receivable | (45,705,722) | (16,318,757) |
| | Increase/(Decrease) in Inventory | 1,067,083 | 12,509,831 |
| | (Increase)/Decrease in Trade and Other Payables | 439,311 | (10,963,156) |
| | Increase/(Decrease) in Advance, Deposit & Prepayments | 152,534 | 1,488,657 |
| | (Increase)/Decrease in Liabilities for Expenses | 1,167,692 | (1,046,667) |
| | (Increase)/Decrease in Liability for contribution to W.P.P.F | (830,645) | (20,329,033) |
| | | **114,987,590** | **177,988,280** |
| | Less: Income Tax Paid | (243,018) | (2,855,287) |
| | **Net Cash Generated from Operating Activities** | **114,744,572** | **175,132,993** |
| **35.00** | **Cash Receipts from Customers** | | |
| | Sales Revenue | 500,490,850 | 571,670,601 |
| | Add: Opening balance of Trade & Other Receivable | 142,812,450 | 126,493,693 |
| | Less: Closing balance of Trade & Other Receivable | (188,518,172) | (142,812,450) |
| | Other Income | 62,276 | 153,337 |
| | **Total** | **454,847,403** | **555,505,181** |



FAMES & R DHAKA BANGLADESH

| Notes | Particulars | Amount in Taka | |
|---|---|---|---|
| | | 30-Jun-2025 | 30-Jun-2024 |
| **36.00** | **Cash Paid to Suppliers** | | |
| | Purchase of Raw Materials | 236,921,231 | 240,564,883 |
| | Purchase of Packing Materials | 11,648,836 | 10,214,018 |
| | Purchase of Spare Parts | 959,985 | 876,697 |
| | Add: Opening balance of Trade Payable | 8,675,058 | 19,502,277 |
| | Less: Closing balance of Trade Payable | (9,235,530) | (8,675,058) |
| | Loss on Foreign Currency rate exchange | - | 115,715 |
| | **Total** | **248,969,581** | **262,598,532** |
| **37.00** | **Cash Paid to Employees** | | |
| | Manufacturing Salary | 9,592,957 | 11,320,813 |
| | Manufacturing Festival Bonus | 782,600 | 827,000 |
| | Manufacturing Overtime | - | 61,147 |
| | Administrative Salary | 12,542,633 | 12,849,002 |
| | Administrative Festival Bonus | 566,900 | 583,500 |
| | Selling & Marketing Salary | 22,103,929 | 22,662,137 |
| | Selling & Marketing Festival Bonus | 1,457,775 | 867,075 |
| | Less: Opening Advance for Salary | - | |
| | Add: Closing Advance for Salary | - | |
| | Add: Opening Liability for Salary | 2,963,344 | 3,498,256 |
| | Less: Closing Liability for Salary | (3,212,069) | (2,963,344) |
| | **Total** | **46,798,069** | **49,705,586** |
| **38.00** | **Cash paid to Others** | | |
| | Total Manufacturing Overhead | 87,724,797 | 94,863,177 |
| | Less: Adjustment for Salary | (10,375,557) | (12,208,960) |
| | Less: Adjustment for Depreciation | (60,996,344) | (64,321,919) |
| | Total Administrative Expenses | 23,994,662 | 24,527,964 |
| | Less: Adjustment for Salary | (13,109,533) | (13,432,502) |
| | Adjustment for Depreciation | (1,471,183) | (1,604,932) |
| | Less: Adjustment for depreciation of the Right Use of Assets | (582,836) | (582,828) |
| | Total Selling & Marketing Expenses | 52,072,862 | 52,372,667 |
| | Adjustment for Salary | (23,561,704) | (23,529,212) |
| | Less: Opening Advance for VAT Current Account | (156,865) | (1,646,006) |
| | Add: Closing Advance for VAT Current Account | 58,055 | 156,865 |
| | Less: Opening Advance for Deposit | (3,671,243) | (3,671,243) |
| | Add: Closing Advance for Deposit | 3,671,243 | 3,671,243 |
| | Less: Opening Advance for Prepayments | (53,724) | (53,240) |
| | Closing Advance for Prepayments | - | 53,724 |
| | Add: Total opening Liability | 13,561,916 | 10,209,945 |
| | Less: Adjustment for opening liability other than others | (9,675,331) | (5,811,605) |
| | Less: Total Closing Liability | (21,767,892) | (13,561,916) |
| | Add: Adjustment for Closing liability other than others | 16,962,340 | 9,675,331 |
| | Less: Cash paid to WPPF | 5,145,043 | 25,518,279 |
| | Less: Adjustment for Packaging Materials Consumed (Note - 25.02.01) | (11,151,620) | (12,452,032) |
| | Less: Adjustment for Spare Parts Consumed (Note - 25.02.02) | (977,155) | (892,779) |
| | Less: Adjustment for Sample | (1,668,928) | (2,203,176) |
| | Less: Closing creditors other than supplier | (109,347) | (230,508) |
| | Add: Opening Creditors other than suppliers | 230,508 | 366,445 |
| | **Total** | **44,092,164** | **65,212,782** |
| **39.00** | **Income Tax Payment** | | |
| | Opening balance of Current Tax Payable | 54,687,916 | 53,299,476 |
| | Add: Current Tax Provision during the Year | 5,430,606 | 4,579,435 |
| | Less: Closing Current Tax Payable | (60,118,522) | (54,687,916) |
| | Less: Opening balance of Advance Tax Payment | (24,177,931) | (24,513,639) |
| | Add: Closing balance of Advance Tax Payment | 24,420,949 | 24,177,931 |
| | **Total** | **243,018** | **2,855,287** |

| Notes | Particulars | Amount in Taka | |
|---|---|---|---|
| | | 30-Jun-2025 | 30-Jun-2024 |
| **40.00** | **Cash paid for acquision of Property, Plant & Equipment** | | |
| | Opening balance of Trade Payable | 732,320 | 732,320 |
| | Add: Purchase/addition during the Year | 39,808,651 | 53,331,212 |
| | Less: Transferred from Capital Work in Progress | - | - |
| | Less: Closing balance of Trade Payable | (732,320) | (732,320) |
| | **Total** | **39,808,651** | **53,331,212** |
| **41.00** | **Cash paid for Capital Work in Progress** | | |
| | Opening balance of Creditors | - | - |
| | Add: Addition during the Year | 54,371,826 | 108,724,739 |
| | Less: Opening balance of Advance for construction | - | - |
| | **Total** | **54,371,826** | **108,724,739** |
| **42.00** | **Cash Dividend Paid** | | |
| | Opening Balance Dividend Payable | 11,647,440 | 6,811,912 |
| | Provision for Cash Dividend during the Year | 6,517,498 | 13,034,996 |
| | Closing Balance of Dividend Payable | (3,414,541) | (11,647,440) |
| | **Total** | **14,750,397** | **8,199,468** |
| **43.00** | **Financial Expenses Paid** | | |
| | Financial Expenses | 9,300,655 | 12,764,833 |
| | Add: Opening Accrued Interest | 6,711,987 | 2,313,349 |
| | Less: Closing Accrued Interest | (13,750,271) | (6,711,987) |
| | Add: Opening Interest Payable on W.P.P.F. Used | 11,275,505 | 11,910,515 |
| | Less: Closing Interest Payable on W.P.P.F. Used | (7,546,555) | (11,275,505) |
| | **Total** | **5,991,321** | **9,001,205** |
| **44.00** | **Principal portion payment of lease liability** | | |
| | Total Lease liability Payment | 690,000 | 690,000 |
| | Less: Interest payment on lease liability | (53,180) | (103,457) |
| | **Total principal portion payment on lease liability** | **636,820** | **586,543** |
| **44.01** | **Interest expenses payment on lease liability:** | | |
| | Opening Accrued Interest | 17,879 | 23,067 |
| | Interest Charged during the period | 58,368 | 98,269 |
| | Closing Accrued Interest | (23,067) | (17,879) |
| | **Interest Paid on lease liability** | **53,180** | **103,457** |

**45.00 Related parties Transaction**

As per International Accounting standards IAS 24 Related Party Disclosures, Parties are considered to be related if one of the party has the ability to control the other party or exercise significant influence over the other party in making financial and operating decision.

**45.01 As per paragraph 17 of IAS 24: Disclosure of key management personnel compensation**

**a) Short-term employee benefits**

The amount of transaction for remuneration and board meeting fee during the year from 1st July 2024 to 30th June 2025 are as follows:

| Name | Designation | Remuneration | Board Meeting fee |
|---|---|---|---|
| Asif Iqbal Chowdhury | Chairman | - | 25,000 |
| Faria Binta Alam | Managing Director | 1,200,000 | 25,000 |
| Wajhi Ahmed | Director | - | 25,000 |
| Kazi Rina Alam | Director | - | 25,000 |
| Md. Tazul Islam | Director | - | 25,000 |
| Mohammad Towhidul Islam | Nominee Director | - | 25,000 |
| Dr. Khandaker Sagir Ahmed | Nominee Director | | 25,000 |
| Sheikh Karimuzzaman | Independent Director | - | 25,000 |
| A.K.M. Delwar Hussain | Independent Director | - | 25,000 |
| **Total** | | **1,200,000** | **225,000** |

**b) Post employment benefits: Nil**

**c) Other long term benefits: Nil**

**d) Termination benefits: Nil**

**e) Share-based payment: Nil**

**46.00 Disclosure as per Companies Act, 1994**

**46.01 Disclosure as per requirement of Schedule XI, Part II, Note 5 of Para 3**

Employee position of the company as at June 30, 2025:

| Salary (Monthly) | Officer & Staff | | Worker | Total Employees |
|---|---|---|---|---|
| | Factory | Head Office | | |
| Below Tk. 3,000 | - | - | - | - |
| Above Tk. 3,000 | 37 | 195 | 85 | 317 |
| For the year ended 30.06.2025 | 37 | 195 | 85 | 317 |

**46.02 Attendance Status of Board Meeting of Directors**

During the year five Board Meetings were held. The attendance status of the meetings are as follows:

| Name of Directors | Duration | Position | Meeting Held | Attended | Total Fee |
|---|---|---|---|---|---|
| Asif Iqbal Chowdhury | 01.07.24 to 30.06.25 | Chairman | 5 | 5 | 25,000 |
| Faria Binta Alam | 01.07.24 to 30.06.25 | Managing Director | 5 | 5 | 25,000 |
| Wajhi Ahmed | 01.07.24 to 30.06.25 | Director | 5 | 5 | 25,000 |
| Kazi Rina Alam | 01.07.24 to 30.06.25 | Director | 5 | 5 | 25,000 |
| Md. Tazul Islam | 01.07.24 to 30.06.25 | Director | 5 | 5 | 25,000 |
| Mohammad Towhidul Islam | 01.07.24 to 30.06.25 | Nominee Director | 5 | 5 | 25,000 |
| Dr. Khandaker Sagir Ahmed | 01.07.24 to 30.06.25 | Nominee Director | 5 | 5 | 25,000 |
| Sheikh Karimuzzaman | 01.07.24 to 30.06.25 | Independent Director | 5 | 5 | 25,000 |
| A.K.M. Delwer Hossain | 01.07.24 to 30.06.25 | Independent Director | 5 | 5 | 25,000 |
| **Total** | | | | | **225,000** |

**46.03 Disclosure as per requirement of Schedule XI, Part II, Para 4**

**Payments to Managing Director and Directors by the Company during the year:**

| Sl. No. | Particulars | 30-Jun-25 |
|---|---|---|
| (a) | Managerial remuneration paid or payable during the year to the directors, including managing director, a managing agent or manager; | 1,225,000 |
| (b) | Expenses reimbursed to the managing agent; | Nil |
| (C) | Commission or other remuneration payable separately to managing agent or his associate; | Nil |
| (d) | Commission or other remuneration payable separately to managing agent or his associate as selling or buying agent of other concerns in respect of contracts entered into by such concerns with the company; | Nil |
| (e) | The money value of the contracts for the sale or purchase of goods and materials or supply of services, entered into by the company with the managing agent or his associate during the financial year; | Nil |
| (f) | Any other perquisites or benefits in cash or in kind; | Nil |
| (g) | Other allowances and commission including guarantee commission; | Nil |
| (h) | Pensions etc.- | Nil |
| | (i) Pensions | Nil |
| | (ii) Gratuities | Nil |
| | (iii) Payments from a provident funds, in excess of own subscription and | Nil |
| | (iv) Compensation for loss of office | Nil |
| | (v) Consideration in connection with retirement from office. | Nil |

**46.04 Disclosure as per requirement of Schedule XI, Part II, Para 7**

**Details of Production Capacity Utilization for the year July-2024 to June-2025**

| Particulars | Unit | License Capacity | Installed Capacity Per Annum | Actual Production per annum | Percentage of Capacity Utilization |
|---|---|---|---|---|---|
| Bolus Products | Pcs | N/A | 15,876,000 | 3,084,155 | 19.43% |
| Powder Products | Kg | N/A | 1,181,250 | 281,452 | 23.83% |
| Liquid Products | Liter | N/A | 1,388,016 | 1,081,245 | 77.90% |

**46.05 Disclosure as per requirement of Schedule XI, Part II, Para 8**

(a) Value of imports calculated on C.I.F basis by the company during the year 2024-2025 in respect of Raw materials, Component and Spare parts and Capital Goods were as follows:

| S.L | Particulars | Import |
|---|---|---|
| | | Amount in BDT |
| i | Raw Materials | - |
| ii | Packing Materials | - |
| iii | Components of Spare parts | - |
| iv | Capital Goods | - |

(b) The Company did not have any expenditure in foreign currency during the financial year on account of Royalty, Know-how, Professional consultancy fees, Interest and other matters.

(c) Value of both imported and Indigenous raw materials, Spare parts and components consumption thereon were as follows:

| Particulars | Total Consumption | Imported Value(in BDT) | (%) | Indigenous Value (in BDT) | (%) |
|---|---|---|---|---|---|
| Raw Materials | 238,049,831 | - | 0.00% | 238,049,831 | 100% |
| Packing Materials | 11,151,620 | - | 0.00% | 11,151,620 | 100% |
| Spare Parts | 977,155 | - | 0% | 977,155 | 100% |
| **Total** | **250,178,607** | - | | **250,178,607** | |

(d) No amount is remitted during the year in foreign currencies on account of dividend with a specific mention of the number of non-residents shareholders, the number of shares held by them on which the dividends were due and the year to which the dividends, related.

(e) Earnings in foreign exchange classified under the following heads as follows:

i) No export made during the year;
ii) No royalty , know -how, professional and consultation fees were received;
iii) No Interest and Dividend received;
iv) No Other income received.

**47.00 Contingent Liabilities**

There is no sum for which the company is contingently liable as on 30.06.2025.

**48.00 Events after the Reporting Period**

Following events occurred since the balance date:

(a) The board of directors recommended 0.50% cash dividend only for general shareholders (Excluding Sponsors and Directors) at the Board meeting held on October 26, 2025 for the year ended June 30, 2025. This dividend is subject to final approval by the shareholders at the forthcoming Annual General Meeting (AGM) of the company.

(b) Except for the fact stated above, no circumstances have arisen since the balance sheet date which would require adjustment to, or disclosure in, the financial statements or notes thereto.

**49.00 Significant Deviation**

Advent Pharma Ltd. is veterinary medicine manufacturer. During the year 2024-2025, our sales has decreased. As a result, net profit after tax and earnings per share has decreased. Net operating cash flow per share has also decreased due to the Accounts Receivable & Paid to Suppliers & Others has increased significantly during the year comparative to the previous year.

# Advent Pharma Ltd.

## Schedule of Property, Plant and Equipment

## As at June 30, 2025

**Annexure-A**
**(Amount in Taka)**

| Particulars | Cost | | | | Depreciation | | | | | Written down value as on 30-June-2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| | Balance as on 01-July-2024 | Addition during the Year | Disposal during the Year | Balance as on 30-June-2025 | Rate of Dep. | Balance as on 01-July-2024 | Charged during the Year | Adjustment during the Year | Balance as on 30-June-2025 | |
| Land | 3,783,816 | - | - | 3,783,816 | 0% | - | - | - | - | 3,783,816 |
| Land Development | 9,454,530 | - | - | 9,454,530 | 2.5% | 1,634,483 | 195,501 | - | 1,829,984 | 7,624,546 |
| Factory Building | 1,245,224,262 | - | - | 1,245,224,262 | 2.5% | 131,763,963 | 27,836,507 | - | 159,600,470 | 1,085,623,792 |
| Plant & Machinery | 394,806,893 | - | - | 394,806,893 | 10% | 114,156,575 | 28,065,032 | - | 142,221,607 | 252,585,286 |
| Sub-Station | 6,694,722 | - | - | 6,694,722 | 10% | 4,077,910 | 261,681 | - | 4,339,591 | 2,355,131 |
| Motor Vehicle | 6,429,369 | - | - | 6,429,369 | 15% | 2,952,214 | 521,573 | - | 3,473,787 | 2,955,582 |
| Furniture & Fixture | 8,284,110 | - | - | 8,284,110 | 10% | 4,422,975 | 386,114 | - | 4,809,089 | 3,475,021 |
| Solar Panel | 2,004,740 | - | - | 2,004,740 | 10% | 1,188,782 | 81,596 | - | 1,270,378 | 734,362 |
| Air Conditioner | 4,254,120 | - | - | 4,254,120 | 10% | 1,791,062 | 246,306 | - | 2,037,368 | 2,216,752 |
| Office Equipment | 6,747,713 | 50,000 | - | 6,797,713 | 10% | 3,613,309 | 317,190 | - | 3,930,499 | 2,867,214 |
| HVAC System & Epoxy Flooring | 44,536,240 | 17,127,376 | - | 61,663,616 | 5% | 14,860,399 | 1,840,612 | - | 16,701,011 | 44,962,605 |
| Laboratory Equipment | 37,356,830 | - | - | 37,356,830 | 5% | 12,400,431 | 1,247,820 | - | 13,648,251 | 23,708,579 |
| Product Development Equipment | 733,341 | 22,631,275 | - | 23,364,616 | 5% | 198,760 | 846,878 | - | 1,045,638 | 22,318,978 |
| ETP | 18,488,470 | - | - | 18,488,470 | 5% | 6,115,249 | 618,661 | - | 6,733,910 | 11,754,560 |
| Books & Journals | 45,000 | - | - | 45,000 | 15% | 31,295 | 2,056 | - | 33,351 | 11,649 |
| **Total** | **1,788,844,156** | **39,808,651** | **-** | **1,828,652,807** | | **299,207,407** | **62,467,527** | **-** | **361,674,934** | **1,466,977,873** |

**Allocation of Depreciation:**

| | |
|---|---|
| Administrative cost | 1,471,183 |
| Factory cost | 60,996,344 |
| **Total** | **62,467,527** |



**Advent Pharma Ltd.**
**Schedule of Property, Plant and Equipment**
**As at June 30, 2024**

**Annexure-A**
**(Amount in Taka)**

| Particulars | Cost | | | | Depreciation | | | | | Written down value as on 30-June-2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| | Balance as on 01-July-2023 | Addition during the Year | Disposal during the Year | Balance as on 30-June-2024 | Rate of Dep. | Balance as on 01-July-2023 | Charged during the Year | Adjustment during the Year | Balance as on 30-June-2024 | |
| Land | 3,783,816 | - | - | 3,783,816 | 0% | - | - | - | - | 3,783,816 |
| Land Development | 9,454,530 | - | - | 9,454,530 | 2.5% | 1,433,969 | 200,514 | - | 1,634,483 | 7,820,047 |
| Factory Building | 1,245,224,262 | - | - | 1,245,224,262 | 2.5% | 103,213,699 | 28,550,264 | - | 131,763,963 | 1,113,460,299 |
| Plant & Machinery | 358,770,184 | 52,311,080 | 16,274,371 | 394,806,893 | 10% | 90,680,223 | 30,620,762 | 7,144,410 | 114,156,575 | 280,650,318 |
| Sub-Station | 6,694,722 | - | - | 6,694,722 | 10% | 3,787,153 | 290,757 | - | 4,077,910 | 2,616,812 |
| Motor Vehicle | 5,427,957 | 1,001,412 | - | 6,429,369 | 15% | 2,397,505 | 554,709 | - | 2,952,214 | 3,477,155 |
| Furniture & Fixture | 8,267,390 | 16,720 | - | 8,284,110 | 10% | 3,994,563 | 428,412 | - | 4,422,975 | 3,861,135 |
| Solar Panel | 2,004,740 | - | - | 2,004,740 | 10% | 1,098,120 | 90,662 | - | 1,188,782 | 815,958 |
| Generator | 627,520 | - | 627,520 | - | 10% | 415,808 | 17,643 | 433,451 | - | - |
| Air Conditioner | 4,254,120 | - | - | 4,254,120 | 10% | 1,517,389 | 273,673 | - | 1,791,062 | 2,463,058 |
| Office Equipment | 6,745,713 | 2,000 | - | 6,747,713 | 10% | 3,265,171 | 348,138 | - | 3,613,309 | 3,134,404 |
| HVAC System | 44,536,240 | - | - | 44,536,240 | 5% | 13,298,513 | 1,561,886 | - | 14,860,399 | 29,675,841 |
| Laboratory Equipment | 51,381,830 | - | 14,025,000 | 37,356,830 | 5% | 15,274,799 | 1,723,376 | 4,597,744 | 12,400,431 | 24,956,399 |
| Product Development Equipment | 20,725,781 | - | 19,992,440 | 733,341 | 5% | 6,140,363 | 612,415 | 6,554,018 | 198,760 | 534,581 |
| ETP | 18,488,470 | - | - | 18,488,470 | 5% | 5,464,027 | 651,222 | - | 6,115,249 | 12,373,221 |
| Books & Journals | 45,000 | - | - | 45,000 | 15% | 28,877 | 2,418 | - | 31,295 | 13,705 |
| **Total** | **1,786,432,275** | **53,331,212** | **50,919,331** | **1,788,844,156** | | **252,010,179** | **65,926,851** | **18,729,623** | **299,207,407** | **1,489,636,749** |

**Allocation of Depreciation:**

| | |
|---|---|
| Administrative cost | 1,604,932 |
| Factory cost | 64,321,919 |
| **Total** | **65,926,851** |

